Abstract：
UNASSIGNED: Many studies on multiple sclerosis (MS) reveal different prevalence and epidemiologic results.
UNASSIGNED: In this study, we aimed to determine the epidemiologic profile of MS using official health records in Turkey.
UNASSIGNED: Patients diagnosed with MS from the official health data of the Ministry of Health, representing the entire population of Turkey, were included in the study. Prevalence and incidence calculations were performed using the data on gender, age, year of birth, city of residence, and year of diagnosis.
UNASSIGNED: As a result of the study, the number of patients with the ICD code G35 was determined as 201,061 and the number of patients with this code entered at least three times was determined as 82,225. The prevalence of MS in Turkey was calculated as 96.4 per 100,000 and the female/male ratio as 2.1/1. The incidence of MS in 2022 was 6.2 per 100,000 and the mean patient age was 43.1 ± 13.3 years (female: 43.0 ± 13.1 vs male: 43.2 ± 13.7) while the mean age at first diagnosis was 34.0 ± 13.0 (female: 33.6 ± 12.6 vs male: 34.9 ± 13.7).
UNASSIGNED: The research was conducted via Official Database of Turkey, which includes population of 85 million and provides valuable insights into the prevalence and incidence rates of this chronic disease.
UNASSIGNED: In this study, we aimed to determine the epidemiologic profile of MS using official health records in Turkey.
UNASSIGNED: Patients diagnosed with MS from the official health data of the Ministry of Health, representing the entire population of Turkey, were included in the study. Prevalence and incidence calculations were performed using the data on gender, age, year of birth, city of residence, and year of diagnosis.
UNASSIGNED: As a result of the study, the number of patients with the ICD code G35 was determined as 201,061 and the number of patients with this code entered at least three times was determined as 82,225. The prevalence of MS in Turkey was calculated as 96.4 per 100,000 and the female/male ratio as 2.1/1. The incidence of MS in 2022 was 6.2 per 100,000 and the mean patient age was 43.1 ± 13.3 years (female: 43.0 ± 13.1 vs male: 43.2 ± 13.7) while the mean age at first diagnosis was 34.0 ± 13.0 (female: 33.6 ± 12.6 vs male: 34.9 ± 13.7).
UNASSIGNED: The research was conducted via Official Database of Turkey, which includes population of 85 million and provides valuable insights into the prevalence and incidence rates of this chronic disease.
摘要：
■许多关于多发性硬化症（MS）的研究揭示了不同的患病率和流行病学结果。
■在这项研究中，我们旨在使用土耳其官方健康记录确定MS的流行病学特征.
■根据卫生部的官方健康数据诊断为MS的患者，代表了土耳其的全体人民，包括在研究中。使用性别数据进行患病率和发病率计算，年龄,出生年份,居住城市,和诊断年份。
■作为研究的结果，ICD代码为G35的患者数量为201,061例,输入该代码至少3次的患者数量为82,225例.土耳其的MS患病率计算为每100,000人中96.4，女性/男性比例为2.1/1。2022年MS的发病率为6.2/100,000，患者平均年龄为43.1±13.3岁（女性：43.0±13.1vs男性：43.2±13.7），而首次诊断的平均年龄为34.0±13.0（女性：33.6±12.6vs男性：34.9±13.7）。
■这项研究是通过土耳其官方数据库进行的，其中包括8500万人口，并为这种慢性疾病的患病率和发病率提供了有价值的见解。
■在这项研究中，我们旨在使用土耳其官方健康记录确定MS的流行病学特征.
■根据卫生部的官方健康数据诊断为MS的患者，代表了土耳其的全体人民，包括在研究中。使用性别数据进行患病率和发病率计算，年龄,出生年份,居住城市,和诊断年份。
■作为研究的结果，ICD代码为G35的患者数量为201,061例,输入该代码至少3次的患者数量为82,225例.土耳其的MS患病率计算为每100,000人中96.4，女性/男性比例为2.1/1。2022年MS的发病率为6.2/100,000，患者平均年龄为43.1±13.3岁（女性：43.0±13.1vs男性：43.2±13.7），而首次诊断的平均年龄为34.0±13.0（女性：33.6±12.6vs男性：34.9±13.7）。
■这项研究是通过土耳其官方数据库进行的，其中包括8500万人口，并为这种慢性疾病的患病率和发病率提供了有价值的见解。
